Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug shield kidneys from autoimmune attack?

NCT ID NCT05946564

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial investigates whether pioglitazone, a drug used for diabetes, can help protect the kidneys in people with ANCA-associated vasculitis—a rare autoimmune disease that causes inflammation of blood vessels, often damaging the kidneys. Participants receive either pioglitazone or a placebo for 6 months, alongside standard immunosuppressive therapy. The goal is to see if pioglitazone reduces protein in the urine and improves kidney function, potentially limiting long-term damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pioglitazone
What this could lead to
If it works, pioglitazone could become a standard add-on therapy to protect kidney function and reduce long-term damage in ANCA vasculitis patients.
What could go wrong
This is a Phase 3 trial with 126 participants, so results may not apply to all patients. Pioglitazone has known risks like fluid retention and potential heart effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis crescentic glomerulonephritis granulomatosis with polyangiitis microscopic polyangiitis rapidly progressive glomerulonephritis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA-ASSOCIATED VASCULITIS CRESCENTIC GLOMERULONEPHRITIS RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS

Contacts and locations

Locations

  • AP-HM - Hôpital la Conception

    RECRUITING

    Marseille, 13005, France

  • AP-HP - Henri Mondor

    RECRUITING

    Paris, 94000, France

  • AP-HP - Hôpital Ambroise-Paré

    RECRUITING

    Paris, France

  • AP-HP - Hôpital Bichat

    RECRUITING

    Paris, 75018, France

  • AP-HP - Hôpital Cochin

    RECRUITING

    Paris, 75015, France

  • AP-HP - Necker enfants malades

    RECRUITING

    Paris, 75015, France

  • AP-HP - Tenon

    RECRUITING

    Paris, 75020, France

  • CH Valenciennes

    RECRUITING

    Valenciennes, 59300, France

  • CH de Boulogne sur Mer

    RECRUITING

    Boulogne-sur-Mer, 62200, France

  • CHU Amiens

    RECRUITING

    Amiens, 80000, France

  • CHU Brest - Hôpital de la Cavale Blanche

    RECRUITING

    Brest, 29200, France

  • CHU Nîmes - Hôpital universitaire Caremeau

    RECRUITING

    Nîmes, 30009, France

  • CHU Pasteur 2 - Nice

    RECRUITING

    Nice, 06000, France

  • CHU d'Angers

    RECRUITING

    Angers, 49933, France

  • CHU de Dijon

    RECRUITING

    Dijon, 21000, France

  • CHU de Grenoble - Hôpital Michalon site nord

    RECRUITING

    Grenoble, 38043, France

  • CHU de Nantes - Hotel Dieu

    RECRUITING

    Nantes, 44093, France

  • CHU de Rouen

    RECRUITING

    Rouen, 76000, France

  • CHU de Strasbourg

    RECRUITING

    Strasbourg, 67000, France

  • CHU de Toulouse - Hôpital Rangueil

    RECRUITING

    Toulouse, 31059, France

  • Centre Hospitalier Départemental Vendée

    RECRUITING

    La Roche-sur-Yon, 85925, France

  • Chru de Nancy

    RECRUITING

    Vandœuvre-lès-Nancy, 54500, France

  • HEGP

    RECRUITING

    Paris, 75015, France

  • Hopital Le Kremlin Bicetre - Aphp

    RECRUITING

    Le Kremlin-Bicêtre, 94270, France

  • Hôpital Robert Schuman (UNEOS)

    NOT_YET_RECRUITING

    Vantoux, 57070, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.